Research Activities

to select and observe the patients, who have recurrent tumors of hematopoietic tissue after transplantation of hematopoietic stem cells, with a view to increasing the efficacy of anti-relapse therapy;
to develop and implement more effective therapy for acute myeloblastic leukemia in adults by using a differentiated approach. The differentiated approach is based on the evaluation of the prognosis, response to the chemotherapy (evaluated based on the dynamics of apoptosis of leukemic cells and markers of the minimal residual disease), escalation of anthracycline doses in the induction and intensive consolidation of remission;
to select the patients with hematopoietic malignancies, obtain primary cell material and to use the material for ex vivo expansion of an autologous hematopoietic stem cell transplant, which will be used for therapy later;
to develop and implement the technology for the transplantation of hematopoietic stem cells with a less intensive conditioning regimen, and to use the technology for treatment of the patients with Hodgkin lymphomas, which recur after autologous hematopoietic cell transplantation;
to study the intensity of expression of pro-and antiapoptotic antigens in terms of bone marrow cells and to assess the efficacy of the therapy for myeloproliferative diseases and primary myelodysplastic syndromes
to obtain autologous mesenchymal stem cell transplants and to use them to treat the patients with multiple sclerosis;
to develop a standard procedure for the procurement of allogeneic stem cell transplants from donors during multi-organ retrieval and to establish the national Cell Therapy Bank;
to develop and implement the procedure according to which the patients with chronic lymphocytic leukemia may make personal decisions in the course of the disease;
to obtain an activated platelet concentrate and to use it for the preparation of a gel for local therapy of nonhealing skin wounds on the limbs of the patients with diabetes mellitus;
to develop and implement the technology for the tandem autologous hematopoietic stem cell transplantation for the treatment of the patients with resistant and recurrent Hodgkin lymphomas;
to develop guidelines for the monitoring and assessment of the medical care provided to the population for the purpose of the Republican epidemiology register of the patients with hematological disorders and to test the register;
to develop the technology for the creation of cryopreserved allografts. To establish a cryopreserved valve allograft bank for the needs of cardiosurgery.